Table 1.
Baseline Characteristics, Ttreatment Course, and Induction Outcomes of Newly Diagnosed ALL.
| Feature | Category | Distribution N=243 N (%) |
|---|---|---|
| Baseline Characteristics | ||
| Age (years) Median age (range) 15 (1-62 y) |
<15 y | 116 (47.7) |
| 15-39 y | 100 (41.2) | |
| 40+ y | 27 (11.1) | |
| Sex | Male | 157 (64.6) |
| Female | 86 (35.4) | |
| Diagnosis subtype | B-ALL | 172 (70.8) |
| T-ALL | 66 (27.2) | |
| MPAL | 5 (2.1) | |
| Extramedullary involvement (N=22) |
CNS | 19 (86.4) |
| Testis | 3 (13.6) | |
| NCI Risk Group | SR | 75 (30.8) |
| HR | 168 (69.2) | |
| TLC (cells*10⁹/L) Median TLC 13.4 (0.11-797.1) |
<50*10⁹/L | 175(72) |
| >50*10⁹/L | 68 (28) | |
| Platelets (cells*10⁹/L) Median (range) 35 (3-612*10⁹/L) |
<20*10⁹/L | 84 (34.6) |
| 21–50*10⁹/L | 73 (30) | |
| >51*10⁹/L | 86 (35.4) | |
| Hemoglobin (g/dL) PS Blasts Median blast% (range) 70% (0-98%) |
Median | 6.9 (1.8-15.40) |
| 0-20% | 72 (29.6) | |
| 21-50% | 27 (11.1) | |
| 51-100% | 144 (59.3) | |
| Philadelphia Chromosome (N=217) |
Normal | 192 (88.5) |
| Mutated | 25 (11.5) | |
| Treatment Characteristics | ||
| Protocol Used | MCP841 | 46 (18.9) |
| BFM95 | 104 (42.8) | |
| GMALL | 32 (13.2) | |
| ICICLE | 61 (25.1) | |
| Intensity (all drugs) | 100 % (maintained) | 140 (55) |
| <100%(not maintained) | 103 (44) | |
| Major Toxicities N=72 | Tumour Lysis Syndrome | 21 (8) |
| Deep Vein Thrombosis | 17 (6) | |
| Peripheral Neuropathy | 15 (6) | |
| Paralytic ileus | 9 (3) | |
| Pancreatitis | 10 (3) | |
| Fever in induction | Present | 131 (49) |
| Induction Outcomes | ||
| Day 8 Steroid response | Poor prednisone response | 27 (11.1) |
| Good prednisone response | 216 (88.9) | |
| Post Induction Outcomes |
Remission | 192 (79) |
| Death in induction | 29 (11.9) | |
| Refractory Disease | 22 (9.1) | |
| MRD N=85 | Positive | 19 (22.4) |
| Negative | 66 (77.6) | |